1. Home
  2. Stocks
  3. Mangalam Share Price

Mangalam Drugs and Organics Share Price

Pharmaceuticals Small Cap

₹111.78 +1.71 (1.55%)

05 Nov, 2024 17:28

SIP TrendupStart SIP in MANGALAM

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹110
  • High
  • ₹112
  • 52 Week Low
  • ₹91
  • 52 Week High
  • ₹145
  • Open Price₹111
  • Previous Close₹110
  • Volume12,168

Investment Returns

  • Over 1 Month -8.95%
  • Over 3 Month -1.9%
  • Over 6 Month + 10.35%
  • Over 1 Year + 10.62%
SIP Lightning

Smart Investing Starts Here Start SIP with Mangalam Drugs and Organics for Steady Growth!

Mangalam Drugs and Organics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 55.8
  • PEG Ratio
  • 0.4
  • Market Cap Cr
  • 177
  • P/B Ratio
  • 1.2
  • Average True Range
  • 4.83
  • EPS
  • -5.7
  • Dividend Yield
  • 0
  • MACD Signal
  • -3.8
  • RSI
  • 38.16
  • MFI
  • 26.73

Mangalam Drugs and Organics Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations76.49101.9497.3481.5687.00
Total Income From Operations76.54102.2497.3481.5687.47
P/L Before Interest, Excpt. Items & Tax4.337.893.35-1.51-6.87
P/L Before Exceptional Items & Tax0.583.940.04-4.75-10.29
P/L After Tax from Ordinary Activities2.683.550.50-3.56-9.54
Net Profit/Loss For the Period2.683.550.50-3.56-9.54
IndicatorMar 24Mar 23
Revenue From Operations [Gross]367.35370.20
Revenue From Operations [Net]367.35370.20
Total Operating Revenues368.59372.25
Total Revenue368.69372.69
Total Expenses379.75370.47
Profit/Loss Before Tax-11.062.21
Profit/Loss For The Period-9.051.27
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity12.1739.52
Net Cash Used In Investing Activity-17.91-22.17
Net Cash Used in Finance Activity5.70-16.62
Net Inc/Dec In Cash And Equivalent-0.040.73
Cash And Equivalent End Of Year1.002.68
IndicatorMar 24Mar 23
Total Share Capital15.8315.83
Total Non-Current Liabilities33.8542.32
Total Current Liabilities180.95165.36
Total Capital And Liabilities357.14359.63
Total Non-Current Assets157.36153.04
Total Current Assets199.78206.58
Total Assets357.14359.63
Indicator20242023
EBIT Margin (%)0.774.02
Return On Capital Employed (%)1.627.70
Return On Equity (%)-6.350.83
Long Term Debt To Equity (%)9.3812.34
Book Value/Share (INR)89.9396.00
IndicatorJun 24Mar 24Dec 23
Net Sales/Income from operations76.49101.9497.34
Total Income From Operations76.54102.2497.34
P/L Before Interest, Excpt. Items & Tax4.337.883.35
P/L Before Exceptional Items & Tax0.583.930.04
P/L After Tax from Ordinary Activities2.683.530.50
Net Profit/Loss For the Period2.683.530.50
IndicatorMar 24
Revenue From Operations [Gross]367.35
Revenue From Operations [Net]367.35
Total Operating Revenues368.59
Total Revenue368.69
Total Expenses379.77
Profit/Loss Before Tax-11.07
Profit/Loss For The Period-9.07
IndicatorMar 24
Net CashFlow - Operating Activity-11.07
Net Cash Used In Investing Activity0.00
Net Cash Used in Finance Activity0.00
Net Inc/Dec In Cash And Equivalent-11.07
Cash And Equivalent End Of Year0.90
IndicatorMar 24
Total Share Capital15.83
Total Non-Current Liabilities33.85
Total Current Liabilities163.79
Total Capital And Liabilities333.42
Total Non-Current Assets157.70
Total Current Assets175.72
Total Assets333.42
Indicator20242023
EBIT Margin (%)0.774.02
Return On Capital Employed (%)1.677.70
Return On Equity (%)-6.680.83
Long Term Debt To Equity (%)9.8312.34
Book Value/Share (INR)85.7996.00

Mangalam Drugs and Organics Technicals

EMA & SMA

Current Price
₹111.78
+ 1.71 (1.55%)
pointer
  • stock-down_img
  • Bullish Moving Average 5
  • stock-up_img
  • Bearish Moving Average 11
  • 20 Day
  • ₹114.54
  • 50 Day
  • ₹118.37
  • 100 Day
  • ₹117.01
  • 200 Day
  • ₹113.69

Resistance and Support

110.96 Pivot Speed
  • R3 119.21
  • R2 116.76
  • R1 113.41
  • S1 107.61
  • S2 105.16
  • S3 101.81

Is Mangalam Drugs and Organics Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Mangalam Drugs & Orgs. has an operating revenue of Rs. 276.11 Cr. on a trailing 12-month basis. An annual revenue de-growth of -1% needs improvement, Pre-tax margin of -3% needs improvement, ROE of -6% is poor and needs improvement. The company has a reasonable debt to equity of 10%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 66 which is a FAIR score but needs to improve its earnings, a RS Rating of 39 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 32 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Mangalam Drugs and Organics Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-08-13 Quarterly Results
2024-05-21 Audited Results
2024-03-15 Others Inter alia to consider and approve: The proposal of Scheme of Merger.
2024-02-13 Quarterly Results
2023-11-08 Quarterly Results

Mangalam Drugs and Organics F&O

Mangalam Drugs and Organics Shareholding Pattern

50.3%
0.11%
0%
44.91%
4.68%
  • NSE Symbol
  • MANGALAM
  • BSE Symbol
  • 532637
  • Chairman & Managing Director
  • Mr. Govardhan Murlidhar Dhoot
  • ISIN
  • INE584F01014

Mangalam Drugs and Organics FAQs

Mangalam Drugs and Organics share price is ₹111 As on 05 November, 2024 | 17:14

The Market Cap of Mangalam Drugs and Organics is ₹176.9 Cr As on 05 November, 2024 | 17:14

The P/E ratio of Mangalam Drugs and Organics is 55.8 As on 05 November, 2024 | 17:14

The PB ratio of Mangalam Drugs and Organics is 1.2 As on 05 November, 2024 | 17:14

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.